Standout Papers

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ej... 2003 2026 2010 2018 2.0k
  1. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial (2003)
    Salim Yusuf, Marc A. Pfeffer et al. The Lancet
  2. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial (2003)
    John J.V. McMurray, Jan Östergren et al. The Lancet
  3. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme (2003)
    Marc A. Pfeffer, Karl Swedberg et al. The Lancet
  4. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial (2003)
    Christopher B. Granger, John J.V. McMurray et al. The Lancet
  5. CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL (2003)
    John J.V. McMurray, Jan Östergren et al. The Lancet
  6. Effects of the Early Administration of Enalapril on Mortality in Patients with Acute Myocardial Infarction (1992)
    Peter Held, J Kjekshus et al. New England Journal of Medicine
  7. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease (2016)
    William R. Hiatt, F. Gerry R. Fowkes et al. New England Journal of Medicine

Immediate Impact

179 standout
Sub-graph 1 of 10

Citing Papers

Heart failure with preserved ejection fraction: everything the clinician needs to know
2024 Standout
Heart Failure With Preserved Ejection Fraction
2023 Standout
57 intermediate papers

Works of Peter Held being referenced

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
2003 Standout
Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design
1999
and 6 more

Author Peers

Author Last Decade Papers Cites
Peter Held 8239 1357 262 2030 37 9.3k
Steven E. McNulty 8620 1352 112 1015 59 9.7k
T. Edward Cuddy 6030 1106 124 782 42 7.3k
Jianjian Gong 6258 658 43 1246 31 7.1k
Janice Pogue 4594 936 509 1395 43 7.6k
P A Poole-Wilson 4475 1426 124 845 77 6.5k
Jean‐Lucien Rouleau 7223 2384 87 1473 123 10.0k
John Wikstrand 4555 1004 101 879 137 6.3k
Greg C. Flaker 8812 2474 494 1014 77 10.3k
Kenneth Dickstein 5514 848 72 832 104 6.9k
Ward A. Riley 6746 2492 49 2339 75 9.9k

All Works

Loading papers...

Rankless by CCL
2026